The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection

Authors

  • Dimitra Ioanna Lampropoulou Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece https://orcid.org/0000-0003-3696-8550
  • Vanessa Meletia Bala Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece https://orcid.org/0000-0003-1423-2489
  • Eleni Zerva Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece https://orcid.org/0000-0002-7974-0321
  • Evangelia Pliakou Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece https://orcid.org/0000-0003-0775-1715
  • Dimitrios Filippou Department of Anatomy and Surgical Anatomy, Medical School, National and Kapodistrian University of Athens, Athens, Greece https://orcid.org/0000-0001-5410-3046
  • Maria Gazouli Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens, Greece https://orcid.org/0000-0002-3295-6811
  • Gerasimos Aravantinos Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece https://orcid.org/0000-0002-2106-1713

DOI:

https://doi.org/10.3855/jidc.15386

Keywords:

SARS-CoV-2, PARP-1 inhibitors, VEGF, bevacizumab, olaparib

Abstract

Introduction: During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments.

Methodology: We reviewed recent literature (Pubmed, Google, Clinicaltrials.gov), as of the middle of May 2021, for evidence regarding the potential benefit from poly(ADP-ribose)-polymerase inhibitors and vascular endothelial growth factor blockade in severe SARS-CoV-2 infection.

Results: poly(ADP-ribose)-polymerase inhibitors have been suggested as potential agents against coronavirus disease 2019 (COVID-19) by a variety of mechanisms. vascular endothelial growth factor-associated vascular permeability is implicated with increased vascular leakage and pulmonary oedema. Thus, anti-angiogenesis factors, such as bevacizumab are being investigated in critically ill COVID-19 patients.

Conclusions: The synergistic potential of these two classes of inhibitors in severe COVID-19 management could be beneficial. Further research should be carried out in order to support this hypothesis.

Author Biographies

Dimitra Ioanna Lampropoulou, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

1. Clinical Trials Unit Leader, PharmD, MSc, PhD, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

2. Member of the Committee for the Medical Information and Advertising Control at National Organization for Medicines (EOF)

3. Post Doctoral Researcher in Cancer Pharmacogenomics at Medical School - National & Kapodistrian University of Athens, Greece.

Vanessa Meletia Bala, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

Medical Oncology Resident, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

Eleni Zerva, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

Research Pharmacist, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

Evangelia Pliakou, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

MD in the Hellenic Navy, MSc, Medical Oncology Resident, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

Dimitrios Filippou, Department of Anatomy and Surgical Anatomy, Medical School, National and Kapodistrian University of Athens, Athens, Greece

1. Presidentof the Greek National Medicines Agency (EOF)

2. Assistant Professor, Department of Anatomy and Surgical Anatomy, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece.

Maria Gazouli, Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

1. Professor, Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece.

2. Member of the European Proteomics Association (EuPA)

3. Visiting Professor at University of Erlangen-Nuremberg and Università degli Studi di Sassari

Gerasimos Aravantinos, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

1. Medical Oncologist, PhD

2. Scientific Director and Head of Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

Downloads

Published

2022-01-31

How to Cite

1.
Lampropoulou DI, Bala VM, Zerva E, Pliakou E, Filippou D, Gazouli M, Aravantinos G (2022) The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection. J Infect Dev Ctries 16:101–111. doi: 10.3855/jidc.15386

Issue

Vol. 16 No. 01: January 2022

Section

Coronavirus Pandemic

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Crossref
Scopus
Google Scholar
Europe PMC